Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Many headaches at night arise due to primary headache disorders, which occur independently of other symptoms and are not caused by another medical condition. Primary headache disorders with nighttime attacks can include tension-type headaches, migraines, hypnic headaches, and cluster headaches. A hypnic headache is sometimes called an "alarm clock headache" because symptoms tend to arise at the same time of night. Apart from considering primary headaches, secondary causes of nighttime headaches should be considered and ruled out, in particular headaches secondary to intracranial hypertension, temporomandibular joint issues (like bruxism) and sleep apnea. Treatments vary based on headache type but often include a combination of medications and prevention strategies. This review article covers the basics of nighttime primary headaches in children, including pathophysiology, etiology, clinical features of the different forms and their treatment. It will also discuss the differences in headache features between children and adults.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12387790 | PMC |
| http://dx.doi.org/10.3390/life15081198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Headache in optic neuritis: A retrospective case-control study revealing clinical and radiological associations of an underrecognized symptom.
Mult Scler Relat Disord
September 2025
Neurologist-Neuroimmunologist. Associate Professor of Neurology, Neuroscience Department, Division of Neurology, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia. Electronic address:
Background: Headache is a common but underrecognized symptom in optic neuritis (ON), with potential implications for diagnosis and management.
Objective: To assess the clinical and radiological factors associated with headache in patients with acute ON.
Methods: We conducted a retrospective case-control study in a tertiary hospital in Bogotá, Colombia (2022-2024).
No Increase in Blood Pressure Assessed With the 24-h Holter Monitoring in Patients With Episodic Migraine During Early Treatment With Anti-CGRP Monoclonal Antibodies: A Prospective Observational Study (SAFHYPER).
Eur J Neurol
September 2025
Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy.
Background: Migraine is associated with an increased cardiovascular risk, including hypertension. Anti-calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) are effective preventive treatments, but concerns have been raised about their potential hypertensive effects. Herein, we assess the early changes in blood pressure (BP) during anti-CGRP mAbs treatment in patients with migraine using 24-h Holter monitoring.
View Article and Find Full Text PDFFDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery.
Clin Cancer Res
September 2025
United States Food and Drug Administration, Silver Spring, Maryland, United States.
On August 6, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to vorasidenib (VORANIGO, Servier Pharmaceuticals, LLC) for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 or 2 (IDH1 or IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.
View Article and Find Full Text PDFC2 dorsal root ganglion: the central hub for cervicogenic headache.
Curr Opin Anaesthesiol
October 2025
Division Chief Pain Medicine, Department of Anesthesiology and Perioperative Medicine, University Hospitals Cleveland, Case Western Reserve University, Cleveland, Ohio, USA.
Purpose Of Review: The purpose of this review is to provide an update on the mechanisms of cervicogenic headache and the role of the C2 dorsal root ganglion (DRG) as a central hub for cervicogenic headache.
Recent Findings: The suboccipital muscles have been implicated in the pathogenesis of cervicogenic headaches due to their connections with the dura mater. The myodural bridge (MDB) connects the suboccipital musculature to the spinal dura mater as it passed through the posterior atlanto-occipital and the atlanto-axial interspaces.
Biofeedback therapy using Cerebri for the prevention of migraine attacks in adults with episodic migraine (BioCer): a randomized, wait-list controlled trial - the study protocol.
F1000Res
September 2025
Norwegian Centre for Headache Research (NorHead), Norwegian University of Science and Technology, Trondheim, Norway.
Introduction: Biofeedback is a non-pharmacological treatment option valued for its minimal risk of adverse events and offers a safe alternative for individuals seeking preventive care for migraine. Despite level A evidence for migraine prevention, biofeedback treatment is still unavailable to most patients. We developed a novel medical device (Cerebri) for multimodal biofeedback treatment that omits the need for healthcare personnel involvement.
View Article and Find Full Text PDF